Skip to content
Screener

Merck & Co. MRK Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)

Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$54K-97.4%

Other financials

Income statement

See full
Revenue$16.6B+5.1%
Gross profit$12.2B-0.3%
Net income-$1.3B-130%
EPS (diluted)-$0.54-131%

Balance sheet

See full
Cash & equivalents$6.9B-14.6%
Total debt$56.7B+54.0%
Total equity$41.9B-14.4%
Total assets$129.80B+10.4%

Cash flow

See full
Operating cash flow$5.4B+63.1%
CapEx$893.0M+16.9%
Free cash flow$4.5B+77.0%

Valuation

See full
Market cap$317.57B+60.3%
Enterprise value$367.4B+61.9%
P/E100.1×+88.0×
P/S4.8×+1.7×

Profitability

See full
Gross margin73%-3.6pp
Net margin4.8%-21.0pp
FCF margin24.1%+1.0pp

Returns & leverage

See full
Return on equity7%-28.5pp
Debt / equity1.4×+0.6×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.

The source filing: Merck & Co.’s 10-K, filed February 24, 2026.

Filed
Feb 24, 2026, 4:15 PM EST
Fiscal year
FY2026
Accession
0000310158-26-000063

Aggregate amortization expense primarily recorded within Cost of sales was $2.8 billion in 2025, $2.4 billion in 2024 and $2.0 billion in 2023. The estimated aggregate amortization expense for each of the next five years is as follows: 2026, $3.8 billion; 2027, $3.6 billion; 2028, $3.3 billion; 2029, $3.0 billion; 2030, $2.7 billion.

Item 8.Financial Statements and Supplementary Data.

FAQ

What is Merck & Co.'s finite-lived intangible assets - expected amortization expense (year one)?
Merck & Co. (MRK) reported finite-lived intangible assets - expected amortization expense (year one) of $3B in Q4 2025.
How has Merck & Co.'s finite-lived intangible assets - expected amortization expense (year one) changed year-over-year?
Merck & Co.'s finite-lived intangible assets - expected amortization expense (year one) increased by 66.7% year-over-year, from $1.8B to $3B.
What is the long-term trend for Merck & Co.'s finite-lived intangible assets - expected amortization expense (year one)?
Over 5 years (2020 to 2025), Merck & Co.'s finite-lived intangible assets - expected amortization expense (year one) has grown at a 18.2% compound annual growth rate (CAGR), from $1.3B to $3B.
What does finite-lived intangible assets - expected amortization expense (year one) mean?
This metric forecasts the amortization expense expected to be recognized in the upcoming fiscal year for intangible assets with finite useful lives. It provides visibility into the non-cash earnings impact of previously acquired intangible assets. Analysts use this to refine future earnings projections and cash flow models.

Ask your AI about Merck & Co.'s finite-lived intangible assets - expected amortization expense (year one).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude